Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director Declaration

27 May 2026 07:00

RNS Number : 7763F
Oxford Biomedica PLC
27 May 2026
 

OXB

Director Declaration

 

Oxford, UK - 27 May 2026OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independent Non-Executive Director has been appointed as a Non-Executive Director of Stevanato Group S.p.A, a NASDAQ listed company with effect from 26 May 2026.

 

-Ends-

 

Enquiries:

OXB:

Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Angela Gray

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNAFMPTMTBTBLF
Date   Source Headline
31st Jul 20207:00 amRNSOXB Signs Clinical Supply Agreement with Axovant
20th Jul 20204:23 pmRNSOXB notes interim results from AZ on AZD1222
3rd Jul 202010:45 amRNSDirector Dealings / Market Share Purchase
2nd Jul 20203:39 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 20201:34 pmRNSDirector Dealings / Market Share Transactions
1st Jul 20206:30 pmRNSHoldings in Company
1st Jul 20203:44 pmRNSBlock listing Return
1st Jul 20209:13 amRNSTotal Voting Rights
30th Jun 20203:23 pmRNSGrant of options
25th Jun 20209:44 amRNSHolding(s) in Company
24th Jun 202011:45 amRNSHoldings in Company
24th Jun 20209:54 amRNSDirector Dealings / Share Disposal – Replacement
24th Jun 20207:00 amRNSDirector Dealings / Market Share Purchase
23rd Jun 20204:46 pmRNSResult of Annual General Meeting
23rd Jun 20202:47 pmRNSAdmission of shares and Total Voting Rights.
23rd Jun 20207:00 amRNSAnnual General Meeting
19th Jun 20203:26 pmRNSInformation in Relation to Annual General Meeting
19th Jun 20207:00 amRNSResult of Placing
18th Jun 20205:33 pmRNSProposed Placing of new Ordinary Shares
8th Jun 20204:01 pmRNSUpdate on Sanofi Ophthalmology Programmes
8th Jun 20207:00 amRNSFive Year Collaboration Agreement signed with VMIC
1st Jun 20209:06 amRNSTotal Voting Rights
1st Jun 20207:00 amRNSDr Roch Doliveux appointed Non-Executive Chairman
28th May 202012:16 pmRNSClinical & Commercial Supply Agreement with AZ
27th May 202011:26 amRNSDirector Dealings / Market Share Purchase
22nd May 20205:28 pmRNS2019 Annual report and Accounts & AGM Notification
20th May 20202:34 pmRNSHolding(s) in Company
13th May 20206:02 pmRNSHolding(s) in Company
13th May 20207:00 amRNSOXB receives approval for first two Oxbox suites
11th May 20204:25 pmRNSPDMR Dealings / Market Share sale
6th May 202012:36 pmRNSDirectors Dealings / Market Share Purchases
6th May 20207:00 amRNSPreliminary Results
1st May 20209:05 amRNSTotal Voting Rights
28th Apr 20201:04 pmRNSCompliance with LR 9.2.6ER(1)
24th Apr 202011:48 amRNSDirector/PDMR Shareholding
23rd Apr 20208:38 amRNSHolding(s) in Company
22nd Apr 202012:03 pmRNSKymriah receives FDA RMAT designation in FL
20th Apr 20204:49 pmRNSHolding(s) in Company
16th Apr 20203:17 pmRNSNotice of Results Update
8th Apr 20207:00 amRNSOxford Biomedica joins COVID-19 vaccine Consortium
1st Apr 20209:31 amRNSTotal Voting Rights
25th Mar 20201:06 pmRNSDirector Dealings / Market Share Purchase
20th Mar 20209:56 amRNSDirector/PDMR Shareholding
18th Mar 20207:00 amRNSOxford Biomedica Business Update
18th Mar 20207:00 amRNSLicense & Supply Agreement with Juno Therapeutics
2nd Mar 20209:22 amRNSTotal Voting Rights
26th Feb 20205:55 pmRNSDirector Dealings / Market Share Purchase
3rd Feb 20205:04 pmRNSClass 2 Transaction Announcement
3rd Feb 202011:56 amRNSTotal Voting Rights
3rd Feb 202011:55 amRNSDirector Dealings / Market Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.